PSYC Announces Formation of Advisory Board
January 05 2021 - 8:30AM
InvestorsHub NewsWire
PSYC Announces Formation of Advisory
Board
Company welcomes three leading voices from the
medical, science, and psychotherapeutic
sectors
LAS VEGAS, NV --
January 5, 2021 -- InvestorsHub NewsWire
-- Global Trac Solutions,
Inc. (OTCPink:
PSYC) (“Global” “PSYC” or the “Company”) a digital media leader
within the emerging sector of medicinal psychedelics, is pleased to
announce the formation of the Company’s Advisory Board. Joining its
newly established board is George Y. Salameh, MD, Hyder A. Khoja,
PhD, and Kelli Foulkroud, MS, LPA, LPC, RYT. And as PSYC moves
ahead with its growth within the emerging sectors of medicinal
psychedelics and digital mental health, these advisors bring
tremendous value to the Company through their collective knowledge
and expertise.
“We are
incredibly grateful and privileged to have the opportunity to
welcome such a diverse and highly-skilled group of experts to our
Advisory Board,” said David Flores, Chief Executive Officer of
Global Trac Solutions, Inc. “As we move ahead into our next phase
of growth, I recognize how important it is to surround our
team with experts who have the ability to bring a perspective
that is uniquely and beneficially derived from their many years of
professional and personal experience. It is also quite encouraging
that each of these experts share the passion we have here at PSYC
for not only building a very successful business over the next
several years but utilizing it to contribute to the betterment of
humanity through a collective development and deployment of tools
and resources intended to improve and optimize mental health and
wellbeing.”
Dr. Salameh
brings more than 35 years of experience within the medical
community where he has served in the sectors of family and
emergency practice and has held his California State Medical
License since 1987. In addition to his extensive knowledge and
experience as a physician, Dr. Salameh has also achieved success as
an entrepreneur and as a real estate developer. He has also
provided strategic consulting services for startup biotech and
medical product companies in collaboration with San Diego venture
capitalists for the past ten
years.
Dr. Khoja has
over 19 years of experience in the fields of molecular biology and
genetic engineering and is an expert in translating ideas into
action, including innovation, commercialization, and knowledge
mobilization. His expertise in science and policy domains has led
to a distinguished career in scientific research and business
development with a passion for Molecular Biology and Genetic
Engineering. Dr. Khoja leverages his knowledge in drug discoveries
from plant extracts and analytics to validate consistent
medical-grade plant nano-molecules for therapeutics. Dr. Khoja
received his doctorate (Ph.D.), in 2003 with honors in Molecular
Biology and Genetic Engineering from a French Ivy league: INP-ENSAT
and had his Post-doctoral training from the Michigan State
University a US land grant
university.
Kelli Foulkrod,
MS, LPA, LPC, RYT has worked in the mental health field for over 19
years in a variety of academic and clinical settings. She is a
transpersonal psychotherapist, trauma-informed yoga teacher,
ceremonialist, and psychedelic integration therapist based in
Austin, Texas, and is also licensed in Colorado. For the past ten
years, she has managed her private practice,
the Organic Mental Health
Center, where she has focused
her expertise and energy in supporting healing in trauma and
complex PTSD, pregnant and postpartum women and their families,
reproductive trauma, grief and loss, psychosis, bipolar, OCD, and
treatment resistant
depression.
Over the coming
months, it is the Company’s intent to strategically add additional
experts to its Advisory Board whom it believes may contribute to
its continued growth and emergence as a leader within the sectors
of medicinal psychedelics and digital mental
health.
About Global Trac Solutions, Inc.
(OTCPink:
PSYC)
At Global Trac Solutions we are
integrating media, creativity, and technology to develop and deploy
thought-provoking ideas and solutions that are fostering and
transforming the approach to some of society’s most pressing
matters.
PSYC has expressed its intent and
commitment to positioning itself at the forefront of the
psychedelic revolution and as a resource center for discovering and
understanding the latest research and business opportunities
surrounding psychedelic inspired medicines. In conjunction with the
FDA’s more open-minded approach to psychedelic medicines, and as
several major U.S. cities continue to approve the decriminalization
of psilocybin, investors are speculating that the psychedelic boom
could be bigger than that of cannabis. PSYC is your source for
current investment related news specific to psychedelic medicines
and cutting-edge research improving overall health, moving this
sector into the mainstream.
We believe in a forward-thinking
approach that embraces groundbreaking new technology and
innovations and through the vision of business development we
intend to continue to evolve into these unchartered territories as
the industry leaders of the future. We truly are the right TRAC to
follow.
Forward-Looking Statements
Disclaimer:
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. In some cases, you can
identify forward-looking statements by the following words:
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "ongoing," "plan," "potential," "predict,"
"project," "should," "will," "would," or the negative of these
terms or other comparable terminology, although not all
forward-looking statements contain these words. Forward-looking
statements are not a guarantee of future performance or results and
will not necessarily be accurate indications of the times at, or
by, which such performance or results will be achieved.
Forward-looking statements are based on information available at
the time the statements are made and involve known and unknown
risks, uncertainty and other factors, including the effect of
COVID-19, that may cause our results, levels of activity,
performance or achievements to be materially different from the
information expressed or implied by the forward-looking statements
in this press release. This press release should be considered in
light of all filings of the Company that are disclosed on the OTC
Markets.com website.
Disclaimer: Global Trac
Solutions, Inc. does not in any way encourage or condone the use,
purchase, sale or transfer of any illegal substances, nor do we
encourage or condone partaking in any unlawful activities. We
support a harm reduction approach for the purpose of education and
promoting individual and public safety. If you are choosing to use
psychedelic substances, please do so
responsibly.
Corporate
Contact:
Global Trac Solutions, Inc.
(PSYC)
www.globaltracsolutions.com
(702) 239-1919
psyc@globaltracsolutions.com
OTCPINK:
PSYC
PSYC (PK) (USOTC:PSYC)
Historical Stock Chart
From Oct 2024 to Nov 2024
PSYC (PK) (USOTC:PSYC)
Historical Stock Chart
From Nov 2023 to Nov 2024